Jaguar Health
Open
$7.27
Prev. Close
$7.31
High
$7.27
Low
$7.16
Market Snapshot
$840.56K
-0.0
-188.60
$11.69M
49
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
emptyResult
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Recently from Cashu
Regulatory Changes Propel Innovation in Autonomous Vehicles and Healthcare Solutions
Regulatory Shifts Enhance Autonomous Vehicle Landscape In a significant development for the future of mobility, the National Highway Traffic Safety Administration (NHTSA) proposes amendments to the Fe…
Jaguar Uranium Corp. Unveils Aggressive 2026 Exploration Strategy in Argentina and Colombia
Jaguar Uranium Corp. Moves Forward with Aggressive Exploration Strategy for 2026 Jaguar Uranium Corp. outlines an ambitious exploration strategy aimed at bolstering its uranium portfolio across Argent…
Jaguar Uranium Corp. Partners with Mendoza for Sustainable Uranium Resource Development
Jaguar Uranium Corp. Partners with Mendoza Ministry for Sustainable Resource Development Jaguar Uranium Corp. (NYSE American: JAGU) enters a pivotal phase in its strategy for responsible uranium resou…
Jaguar Uranium Gains Environmental Approval for Major Laguna Salada Uranium Project Development.
Jaguar Uranium Receives Key Environmental Approval for Laguna Salada Project Jaguar Uranium Corp. announces significant progress in its Laguna Salada project in Chubut, Argentina. The Ministry of Envi…